RGS17

Across TCGA pan-cancer cohorts, RGS17 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of RGS17’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where RGS17 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RGS17 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

LUAD, KIRP, and THCA are the cancer types where RGS17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RGS17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	All	+1.849	<.001	11	view →
KIRP	All	III,IV	+1.593	<.001	11	view →
THCA	Male	II,III,IV	−1.175	<.001	9	view →
LIHC	All	All	+0.082	<.001	9	view →
BLCA	Male	III,IV	+1.618	.005	6	view →
LUSC	All	II,III,IV	+0.672	<.001	6	view →
KIRC	Male	All	+0.295	<.001	6	view →
CHOL	All	All	+1.881	<.001	5	view →
COAD	Male	All	+0.131	.029	3	view →
PRAD	All	All	+0.713	<.001	2	view →
KICH	Female	All	−0.335	.001	2	view →
BRCA	All	All	−0.157	.028	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

RGS17–LUAD

Open the LUAD breakdown →